Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of MK0634 in Postmenopausal Women With Overactive Bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs MK 0634 (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck & Co; Merck Sharp & Dohme
- 05 Oct 2011 Official Title amended as reported by ClinicalTrials.gov.
- 05 Oct 2011 Actual end date (September 2009) added as reported by ClinicalTrials.gov.
- 05 Oct 2011 Primary endpoint identified as reported by ClinicalTrials.gov.